9rules - The best content from the independent web.

Browse 9rules By - Great blogs sorted by topic at 9rules.

Pharma Strategy Blog By Sally Church

Member Since 2009 of the Science Community

Recent Posts

Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone »

Posted May 25, 2012

Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases »

Posted May 22, 2012

Reflections of a Medical Oncologist on AACR 2012 »

Posted May 18, 2012

ASCO 2012 Preview – Highlights of key data emerging from Chicago »

Posted May 15, 2012

ASCO 2012 Acronym Mania! »

Posted May 14, 2012

Ribonucleases (RNase) – clinical applications for cancer therapy »

Posted May 01, 2012

Ribonucleases (RNase) what are they and why are they relevant to cancer? »

Posted Apr 30, 2012

Highlights of AACR 2012 – Part 3 »

Posted Apr 23, 2012

Highlights of AACR 2012 – Part 2 »

Posted Apr 18, 2012

Highlights of AACR 2012 – Part 1 »

Posted Apr 17, 2012

American Society for Cancer Research Meeting 2012 »

Posted Mar 31, 2012

On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer »

Posted Mar 23, 2012

J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer »

Posted Mar 08, 2012

The importance of metabolism in cancer research »

Posted Mar 06, 2012

nab-Paclitaxel and its potential role in pancreatic cancer »

Posted Mar 05, 2012

Video Report from 2012 European Association of Urology Congress in Paris »

Posted Mar 02, 2012

We the People… »

Posted Feb 29, 2012

The challenge of prostate cancer drug approval versus reimbursement »

Posted Feb 27, 2012

Will combining custirsen and MDV3100 reduce resistance in advanced prostate cancer? »

Posted Feb 26, 2012

Combined VEGF and MET inhibition in some cancers may be better than either alone »

Posted Feb 24, 2012

Signup now or login below. Save your favorites, customize the content, and a lot more.

Advertise Here



More Science Members View All Members

9rules Supporters